Regulatory and Compliance Updates news (page 8)

• 

  21 April 2026

  Siemens expands Industrial Edge for enhanced data and AI integration

  Industrial Edge: AI Suite & WinCC Unified GA. Management adds IEC62443 security and air‑gap. Information Hub gets bidirectional sync and ARM support. New machine‑vision and rugged HW partners.
• 

  21 April 2026

  LANXESS at IFAT 2026: Filtration for PFAS, Phosphorus, Micropollutants and UPW

  IFAT showcase: ion‑exchange resins and adsorbents for regenerable phosphorus removal (Bayoxide E IN 20), PFAS and fluoride (MDS/TP resins), micropollutants (VP OC), and the LewaPlus design tool.
• 

  21 April 2026

  LKAB advances Luleå critical‑minerals demonstration plant

  Installation underway at demo facility; building complete, commissioning autumn. Malmberget pilot tests the chain. Tech will extract phosphorus and 17 REEs from iron‑ore residues; permits ongoing.
• 

  21 April 2026

  FDA accepts Roche sBLA for Gazyva/Gazyvaro in systemic lupus erythematosus (SLE)

  ALLEGORY phase III: SRI‑4 response 76.7% vs 53.5% (adj diff 23.1%), doubled remission rates, fewer flares and reduced steroid use. FDA decision expected by Dec 2026.
• 

  20 April 2026

  FDA Accepts Genentech sBLA for Gazyva in SLE

  FDA accepted sBLA for an anti‑CD20 in SLE after Phase III ALLEGORY: SRI‑4 responders 76.7% vs 53.5%, higher remission, fewer flares and steroid reduction; decision due Dec 2026.
• 

  20 April 2026

  PPG launches end-to-end data center protective coatings and application services

  At Data Center World: demos of IEEE/UL‑compliant coating systems plus application and paint‑line design services; features EMI shielding, fire and corrosion protection, thermal reflectivity.

• 

  20 April 2026

  Merck: FDA grants priority review for KEYTRUDA/KEYTRUDA QLEX with Padcev in cisplatin‑eligible MIBC

  FDA granted priority review for two sBLAs after Phase 3 KEYNOTE‑B15 showed EFS and OS benefit; PDUFA Aug 17, 2026. If approved, first perioperative options for MIBC regardless of cisplatin eligibility.
• 

  20 April 2026

  Novo Nordisk: Etavopivat meets phase‑3 HIBISCUS endpoints — reduces VOCs and increases haemoglobin in sickle cell disease

  HIBISCUS phase‑3 (n=385, ≥12 yrs): etavopivat cut VOCs by 27% and delayed first VOC ~4 months; 48.7% had >1 g/dL Hb rise at 24 weeks vs 7.2% placebo. Well tolerated; filing H2 2026.
• 

  20 April 2026

  Siemens and Vulcan Energy team up to scale Europe’s sustainable lithium supply

  Framework deal names a preferred automation/digitalization supplier for Lionheart, Europe's first integrated lithium+renewables project: 24,000 t LHM/yr; 275 GWh power; 560 GWh heat; 30-yr life
• 

  20 April 2026

  Asahi Kasei Acquires Aicuris to Expand Infectious-Disease Pharma Portfolio

  Acquisition adds three antiviral assets - royalties from Prevymis, pritelivir (FDA Priority Review; PDUFA Q4 2026) and AIC468 - aims $500M revenue by 2030 and transplant/infectious-disease growth.
• 

  20 April 2026

  GSK's Blenrep approved in China for 2L+ relapsed/refractory multiple myeloma

  Approved with bortezomib+dexamethasone for adults after ≥1 prior line; DREAMM‑7: 3x PFS (36.6 vs 13.4m) and 42% lower death risk; outpatient ADC; ocular AEs manageable.
• 

  17 April 2026

  EMA recommends Nobivac NXT HCPChFeLV, EU’s first self‑amplifying RNA cat vaccine

  Protects cats vs five pathogens (herpes, calici, panleuk, FeLV, Chlamydia). Trials show adequate immunity, reduced disease/shedding; 1–3 yr protection; well tolerated.
• 

  17 April 2026

  European Commission approves Merck’s ENFLONSIA for infant RSV prevention

  Single 105 mg IM, non-weight-based dose gives ~5 months' RSV protection; trials showed ~60% fewer medically attended LRIs and ~84% fewer RSV hospitalizations; safety similar to placebo
• 

  16 April 2026

  Repsol to raise oil production in Venezuela

  Agreed with Venezuela and PDVSA to resume Petroquiriquire operations, ensure payments and raise output 50% in 12 months and 3x in 3 years if conditions hold; OFAC GL50A permits transactions.
• 

  16 April 2026

  Rotterdam bunker sales down 25% in Q1 2026

  Largest declines in fossil oils: VLSFO -44%, HSFO -25%, ULSFO -13%; MGO -7%, MDO -11%. (Bio-)LNG & methanol +6.4%, bioblends +2.7%; RED III, pricing, regs cited.
• 

  16 April 2026

  Lilly ACHIEVE‑4 confirms Foundayo cardiovascular safety and cardiometabolic benefits

  ACHIEVE-4: Foundayo non-inferior vs insulin glargine for MACE-4 (HR 0.84); improved A1C (-1.6 vs -1.0) and weight (-8.8% vs +1.7%) at 52 wks; 57% lower all-cause death; GI AEs; FDA filing planned.
• 

  14 April 2026

  ERA launches to accelerate clean hydrogen for EU industrial competitiveness and energy independence

  CEO-led alliance published a white paper urging governments to boost demand certainty, lower electricity costs, simplify RFNBO rules, de-risk finance and fund a hydrogen backbone to speed FIDs.
• 

  14 April 2026

  RWE installs two substations for Nordseecluster A

  Two offshore substations (~40×22 m; 1,800 & 2,500 t) were installed ~50 km north of Juist after transport from Saint‑Nazaire by heavy‑lift Gulliver. Nordseecluster A: 660 MW (2027); B: +900 MW (2029)
• 

  14 April 2026

  thyssenkrupp-backed European Resilience Alliance launches to scale clean hydrogen deployment

  CEO-led alliance white paper diagnoses bottlenecks—fragmented rules, high power costs, weak demand certainty—and urges bankable demand, simpler support, de-risk finance and cross-border infrastructure
• 

  14 April 2026

  Novo Nordisk partners with OpenAI to speed drug discovery and delivery

  Integrate advanced AI across drug discovery, manufacturing, supply chain and commercial ops to speed development, upskill staff; pilots now, full integration by end-2026; strict governance.
• 

  13 April 2026

  Clariant launches Hostapon CT solid, a salt-free mild taurate surfactant

  New surfactant offers 90% actives, long-lasting silky foam, strong oil stability, low-salt formulation flexibility, mildness for dry/sensitive skin, 80% RCI and ready biodegradability.
• 

  13 April 2026

  Daiichi Sankyo and Merck: FDA Priority Review for Ifinatamab Deruxtecan in ES‑SCLC

  BLA for ifinatamab deruxtecan accepted and granted FDA Priority Review for adult ES‑SCLC post‑platinum therapy; PDUFA Oct 10, 2026. Based on IDeate‑Lung01 Phase 2 (B7‑H3 DXd ADC).
• 

  13 April 2026

  Johnson & Johnson reports positive 12‑month VARIPULSE results at EHRA 2026

  12‑month post‑market study: 84.2% freedom from atrial arrhythmia (90.5% paroxysmal; 75.3% persistent); 0.8% primary adverse events; CE‑mark allows ablation beyond pulmonary veins
• 

  13 April 2026

  Lilly: Jaypirca plus venetoclax‑rituximab extends PFS in previously treated CLL/SLL

  Phase 3 BRUIN CLL-322 (n=639) in relapsed/refractory CLL/SLL: time-limited (2-yr) pirtobrutinib with venetoclax+rituximab showed consistent benefit across subgroups; safety similar; OS immature.
• 

  13 April 2026

  Roche's Elecsys NfL CE‑marked to monitor neuroinflammation in RRMS

  New blood test detects neuroaxonal damage, enabling minimally invasive, more accessible monitoring of neuroinflammation, complementing MRI and supporting earlier clinical intervention
• 

  10 April 2026

  Johnson & Johnson: TECNIS PureSee IOL Shows Strong Contrast Sensitivity and Extended Range of Vision

  Real-world and randomized trials show excellent distance/intermediate vision, some near gain, high satisfaction, low visual disturbances and strong tolerance to residual refractive error.
• 

  9 April 2026

  Novo Nordisk: Wegovy injection approved for up to 48-hour controlled‑temperature delivery in the EU

  EMA change reduces last‑mile cold‑chain needs, lowering packaging/transport costs, enabling discrete home and online dispensing; SmPC updated for healthcare providers; patient leaflet unchanged.
• 

  9 April 2026

  Evonik showcases high-performance polymers and additives at CHINAPLAS 2026

  Highlights materials for energy transition, EV battery cooling, eVTOL structures, hydrogen, smart manufacturing, 3D-printed medical implants, recycling additives and doubled PA12 capacity
• 

  9 April 2026

  Boehringer Ingelheim and BioNTech partner on ES‑SCLC immunotherapy trial

  Phase Ib/II trial will test DLL3/CD3 T‑cell engager plus PD‑L1/VEGF‑A bispecific in extensive‑stage SCLC to boost durable antitumor immunity; dosing to start H2 2026
• 

  8 April 2026

  Infinium’s Project Atlas Wins SABA Next‑Gen SAF Procurement

  Selected eSAF project will supply SAF certificates via book-and-claim; airline to take delivery and manage logistics. ~100,000 MTPA, ~95% lifecycle CI reduction, RFNBO-compliant; production by 2029